Chlorpheniramine inhibits the ornithine decarboxylase induction of Ehrlich carcinoma growing in vivo.
The antihistaminic (+/-)-chlorpheniramine significantly reduced the progression of Ehrlich carcinoma when it was administered at 0.5 mg/mouse/day from the third day on, after tumour inoculation. The ODC activity of tumour cells was diminished by 70% on day 7 after tumour transplantation, when maximum ODC activity is detected in non-treated tumour growing 'in vivo'. Northern blot analyses indicated that the inhibitory effect of this 1,4-diamine takes place at a post-transcriptional level. Results obtained from serum-free cultured cells indicated that chlorpheniramine inhibits the ODC synthesis rate.
Urdiales
J L
JL
Cátedra de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Málaga, Spain.
Matés
J M
JM
Núñez de Castro
I
I
Sánchez-Jiménez
F M
FM
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002744:Chlorpheniramine / Q000494:pharmacology*; D004790:Enzyme Induction / Q000187:drug effects; D051379:Mice; D009955:Ornithine Decarboxylase / Q000096:biosynthesis / Q000187:drug effects*; D065108:Ornithine Decarboxylase Inhibitors; D012333:RNA, Messenger / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
D065108:Ornithine Decarboxylase Inhibitors; D012333:RNA, Messenger; D002744:Chlorpheniramine; D009955:Ornithine Decarboxylase